Guardant Health, Inc. (FRA:5GH)

Germany flag Germany · Delayed Price · Currency is EUR
93.00
+2.04 (2.24%)
At close: Dec 5, 2025
176.13%
Market Cap 11.30B
Revenue (ttm) 769.26M
Net Income (ttm) -339.89M
Shares Out n/a
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 26
Open 93.00
Previous Close 90.96
Day's Range 93.00 - 93.00
52-Week Range 28.95 - 96.16
Beta n/a
RSI 65.95
Earnings Date Feb 20, 2026

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2011
Employees 2,021
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5GH
Full Company Profile

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.